FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae‐Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, See‐Tong Pang, Jian‐Ri Li, Xavier García del Muro, Florence Joly, Zsuzsanna Pápai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Robert Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn
To our knowledge, these are the first data to compare FGFR-directed therapy with chemotherapy in patients with <i>FGFR</i>-altered UC, showing comparable efficacy and manageable safety. Exploratory testing suggested <i>FGFR3</i> DNA alterations in association with <i>FGFR1</i>/<i>3</i> mRNA overexpression may be better predictors of rogaratinib response.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.